ESMO 2019 — Controversy — Should therapy be de-escalated in patients with HPV+ oropharyngeal cancer?


  • Michael Simm
  • Oncology Conference reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Delegates voted twice on whether the time has come to de-escalate treatment in HPV+ oropharyngeal cancer (OPC) — at the beginning of a controversy session and after 2 experts had presented their views.

Summary

  • Both presenters agreed that positive clinical trials are required before de-escalation can be undertaken.
  • Hisham Mehanna was a self-confessed “de-escalationist” for 10 years. Based on 3 recent studies, he has now completely changed his mind.
  • In the first vote, 43.6% of delegates said we should de-escalate treatment for HPV+ OPC, while 29.5% said “No”.
  • In the second vote, opinions had changed with 21.8% voting “Yes” and 67.3% “No”.

Yes, treatment should be de-escalated — Christian Simon, Lausanne, Switzerland

  • The rates of late toxicity seen in pivotal trials have steadily increased over the last 25 years from approximately 18% to almost 50%.
  • Grade 3 toxicity for the oesophagus translates to liquids only, which may still result in pain on swallowing and may require dilation.
  • The death rate unrelated to cancer was 36% with chemoradiotherapy vs 18% with radiotherapy until 2012 (Forastiere et al. Journal of Clinical Oncology, 2013).
  • The incidence of aspiration pneumonia keeps increasing for at least 10 years after therapy and reaches 30%+ in patients over 75 years of age (Xu et al. Cancer, 2015).
  • Not having dysphagia is the second highest priority for patients (Ramaekers et al. Oral Oncology, 2011).
  • Qualifier: De-escalation is not for everyone and it should be done only once we have done the trials.

No, treatment should not be de-escalated — Hisham Mehanna, Birmingham, UK

  • The 3-year survival rate for low-risk HPV+ OPC is 93%, “and that rate comes at a cost.”
  • There are no alternative treatment regimes (to cisplatin and radiotherapy) with similar survival but less toxicity.
  • Patients want de-escalation only if there is no survival detriment. 37% would accept no reduction in survival at all. If the reduction of survival would be 5% or less for radiotherapy alone, 69% would rather choose chemoradiotherapy (Brotherston et al. Head Neck, 2012).
  • Replacing cisplatin with cetuximab did not work and resulted in worse overall survival. The absolute difference after 2 years was 23.8% (Mehanna et al. Lancet, 2018).
  • Just in are the results of phase 2 NRG-HN002 trial on p16-positive, non-smoking-associated, locoregionally advanced oropharyngeal cancer that failed to prove non-inferiority when radiotherapy was given without cisplatin (Yom S et al. ASTRO meeting 2019).